GAZYVA®

(Obinutuzumab)

Documentation

Patented
Approved 2013
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: ADCC Agonist
Target: CD20
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA